| 1.82 Data as of Mar 14 |  -0.02 / -1.09%Today’s Change | 1.31 Today|||52-Week Range 7.24 | +10.30% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $136.8M |
Company Description
GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways for the treatment of cancer, cancer supportive care, and other serious medical conditions. GTx markets its products such as Fareston for the treatment of breast cancer, Ostarine for the treatment of muscle wasting in patients with cancer, Capesaris for first line treatment of advanced toremifene to reduce fractures and treat other estrogen deficiency side effects of ADT in men with prostate cancer. The company is developing selective androgen receptor modulators, a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer, and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.
Employees
Shareholders
| Other institutional | 6.19% |
| Individual stakeholders | 58.00% |
| Mutual fund holders | 5.20% |
Top Executives
| Mitchell Shuster Steiner | Vice Chairman & Chief Executive Officer |
| Marc Steven Hanover | President, COO, CFO & Head-Investor Relations |
| James T. Dalton | Chief Scientific Officer & Vice President |
| K. Gary Barnette | VP-Clinical Research & Development Strategy |
| Ronald A. Morton | Chief Medical Officer & Vice President |
.
